Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Advancing a new drug to market requires substantial investments in time as well as financial resources. Crucial bioactivities for drug candidates, including their efficacy, pharmacokinetics (PK), and adverse effects, need to be investigated during drug development. With advancements in chemical synthesis and biological screening technologies over the past decade, large amount of biological data points for millions of small molecules have been generated and are stored in various databases. These accumulated data, combined with new machine learning (ML) approaches, such as deep learning, have shown great potential to provide insights into relevant chemical structures to predict in vitro, in vivo, and clinical outcomes, thereby advancing drug discovery and development in the big data era.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Cortes, C., & Vapnik, V. (1995) · Machine Learning · doi:10.1007/bf00994018 · Cited by 59,421 · cited 2×
“These QSAR models were developed using classic ML algorithms, such as random forest [36], support vector machines (SVMs) [37], and k-nearest neighbors [38], and the molecular descriptors [39] describing the chemical structures.”
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Some Studies in Machine Learning Using the Game of Checkers
Samuel, A. L. (1959) · IBM Journal of Research and Development · doi:10.1147/rd.33.0210 · Cited by 4,443
Golbraikh, A., & Tropsha, A. (2002) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(01)00123-1 · Cited by 3,735 · cited 1×
“In the same period, model validation was emphasized and treated as a crucial component of modeling procedures [128].”
MethodHMDB 4.0: the human metabolome database for 2018
Wishart, D. S., Feunang, Y. D., Marcu, A., Guo, A. C., Liang, K., Vázquez-Fresno, R., Sajed, T., Johnson, D., Li, C., Karu, N., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1089 · Cited by 3,438
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules
Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru-Guzik, A. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00572 · Cited by 3,106
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Wu, X., Zhu, X., Wu, G.-Q., & Ding, W. (2014) · IEEE Transactions on Knowledge and Data Engineering · doi:10.1109/tkde.2013.109 · Cited by 2,410
Artificial intelligence in medicine
Hamet, P., & Tremblay, J. (2017) · Metabolism · doi:10.1016/j.metabol.2017.01.011 · Cited by 2,334
p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure
Hansch, C., & Fujita, T. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a035 · Cited by 2,313 · cited 1×
“Since the QSAR approach was first developed by Hansch and Fujita in 1964 [123], it has remained an efficient method to find a statistically significant correlation between chemical structures and their properties and activities.”
MethodThe Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970 · cited 1×
“In addition to HTS and novel testing approaches, the advent of pharmacogenomics, made possible by the completion of the Human Genome Project (HGP), has spurred major advances in new drug development, including precision medicines and targets for diseases [11].”
MethodThe rise of deep learning in drug discovery
Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.039 · Cited by 1,770
Reactome: a database of reactions, pathways and biological processes
Croft, D., O'Kelly, G., Wu, G., Haw, R., Gillespie, M., Matthews, L., Caudy, M., Garapati, P., Gopinath, G., Jassal, B., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1018 · Cited by 1,751
Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks
Segler, M. H. S., Kogej, T., Tyrchan, C., & Waller, M. P. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00512 · Cited by 1,537
Deep Neural Nets as a Method for Quantitative Structure–Activity Relationships
Ma, J., Sheridan, R. P., Liaw, A., Dahl, G. E., & Svetnik, V. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500747n · Cited by 1,159 · cited 1×
“…in virtual screening were highlighted in the QSAR ML challenge supported by Merck in 2012, and the winning team used an ensemble of different ML methods including deep neural networks (DNN) and showed significantly better performance than other ML approaches in their following study [160].”
MethodDeepTox: toxicity prediction using deep learning
Mayr, A., Klambauer, G., Unterthiner, T., & Hochreiter, S. (2016) · Frontiers in Environmental Science · doi:10.3389/fenvs.2015.00080 · Cited by 1,081 · cited 2×
“In this competition, DeepTox, a computational toxicity model based on deep learning, exhibited the highest performance of all computational methods [164].”
BackgroundMethodArtificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018 · cited 1×
“Besides QSAR, there are many other ML applications in drug discovery and development [141].”
BackgroundBiGG Models: A platform for integrating, standardizing and sharing genome-scale models
King, Z. A., Lu, J., Dräger, A., Miller, P., Federowicz, S., Lerman, J. A., Ebrahim, A., Palsson, B. O., & Lewis, N. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1049 · Cited by 938
The PDBbind database: methodologies and updates
Wang, R., Fang, X., Lu, Y., Yang, C.-Y., & Wang, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm048957q · Cited by 933
Schneider, G. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.232 · Cited by 910 · cited 2×
“To advance through phases of preclinical and clinical development, drug candidates are extensively tested for their efficacy, PK, and adverse effects [1].”
BackgroundA side effect resource to capture phenotypic effects of drugs
Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J., & Bork, P. (2010) · Molecular Systems Biology · doi:10.1038/msb.2009.98 · Cited by 899
Rethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894
Similarity-based virtual screening using 2D fingerprints
Willett, P. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.005 · Cited by 849 · cited 1×
“…QSAR has reached several milestones, including the development of novel chemical descriptors, including topological descriptors [125] and molecular fingerprints [126,127], and the application of new nonlinear modeling algorithms, such as random forest [36], SVMs [37], and k-nearest neighbors [38].”
BackgroundThe ClinicalTrials.gov Results Database — Update and Key Issues
Zarin, D. A., Tse, T., Williams, R. J., Califf, R. M., & Ide, N. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1012065 · Cited by 838
From machine learning to deep learning: progress in machine intelligence for rational drug discovery
Zhang, L., Tan, J., Han, D., & Zhu, H. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.08.010 · Cited by 760 · cited 1×
“It is necessary to develop novel approaches that systematically address the high volume, multidimensional, and high-sparse data sources needed to prechct drug efficacy and adverse effects in animals and/or humans [28,50].”
BackgroundSelf-citationDeep Learning in Drug Discovery
Gawehn, E., Hiss, J. A., & Schneider, G. (2016) · Molecular Informatics · doi:10.1002/minf.201501008 · Cited by 723 · cited 2×
“Deep learning, based on ANN, was originally presented during the 1980s [156].”
BackgroundSuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647 · cited 1×
“…[51], AICD [52], and e-Drug3D [53]); (iii) collections of drug targets, including genomics and proteomics data (e.g., BindingDB [54], Supertarget [55], and Ligand Expo [56]); (iv) databases storing biological data obtained from assay screening, metabolism, and efficacy studies (e.g., HMDB [57],…”
BackgroundNoninvasive Alcohol Monitoring Using a Wearable Tattoo-Based Iontophoretic-Biosensing System
Kim, J., Jeerapan, I., Imani, S., Cho, T. N., Bandodkar, A., Cinti, S., Mercier, P. P., & Wang, J. (2016) · ACS Sensors · doi:10.1021/acssensors.6b00356 · Cited by 599
How artificial intelligence is changing drug discovery
Fleming, N. (2018) · Nature · doi:10.1038/d41586-018-05267-x · Cited by 546 · cited 1×
“…improvements in computational power coupled with improvements in artificial intelligence (Al) technology, including the development of various deep learning algorithms [117–119], positioned CADD studies to progress to a new stage and capitalize on the rich infrastructure of big data studies [120].”
BackgroundToward interoperable bioscience data
Sansone, S.-A., Rocca-Serra, P., Field, D., Maguire, E., Taylor, C., Hofmann, O., Fang, H., Neumann, S., Tong, W., Amaral-Zettler, L., et al. (2012) · Nature Genetics · doi:10.1038/ng.1054 · Cited by 475
Big data and artificial intelligence modeling for drug discovery
Zhu, H. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023324 · Cited by 455 · cited 1×
“All of these efforts showed potential to be used to prioritize drug candidates with desired therapeutic activities and to exclude unsuitable compounds with adverse effects in a virtual screen during drug discovery [43].”
BackgroundSelf-citationFDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
De Novo Design of Bioactive Small Molecules by Artificial Intelligence
Merk, D., Friedrich, L., Grisoni, F., & Schneider, G. (2018) · Molecular Informatics · doi:10.1002/minf.201700153 · Cited by 373
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Binding MOAD (Mother Of All Databases)
Hu, L., Benson, M. L., Smith, R. D., Lerner, M. G., & Carlson, H. A. (2005) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20512 · Cited by 328
Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation
Fourches, D., Muratov, E., & Tropsha, A. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00129 · Cited by 294 · cited 1×
“These features (venue, vocabulary, and variety) highlight the urgent need to develop universal criteria for data harmonization [75–78].”
BackgroundQuantitative Structure−Activity Relationship Modeling of Rat Acute Toxicity by Oral Exposure
Zhu, H., Martin, T. M., Ye, L., Sedykh, A., Young, D. M., & Tropsha, A. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900189p · Cited by 287
Self-citationBioModels: ten-year anniversary
Chelliah, V., Juty, N., Ajmera, I., Ali, R., Dumousseau, M., Glont, M., Hucka, M., Jalowicki, G., Keating, S., Knight-Schrijver, V., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1181 · Cited by 281
Xu, Y., Pei, J., & Lai, L. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00244 · Cited by 250
A renaissance of neural networks in drug discovery
Baskin, I. I., Winkler, D., & Tetko, I. V. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1201262 · Cited by 235
Ciallella, H. L., & Zhu, H. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00393 · Cited by 227 · cited 2×
“There are ‘ten Vs’ characteristics that are intrinsic for big data in drug discovery [24–26] (Figure 1): include volume, velocity, variety, veracity, validity, vocabulary, venue, visualization, volatility, and value [27,28] (Box 1).”
BackgroundSelf-citationZhu, H., Zhang, J., Kim, M. T., Boison, A., Sedykh, A., & Moran, K. (2014) · Chemical Research in Toxicology · doi:10.1021/tx500145h · Cited by 154 · cited 1×
“Read-across is becoming increasing used in the identification of chemical toxicity liabilities, including the prediction of adverse effects for drugs and in the evaluation of personal care products [78,107,108].”
BackgroundSelf-citationComparing Multiple Machine Learning Algorithms and Metrics for Estrogen Receptor Binding Prediction
Russo, D. P., Zorn, K. M., Clark, A. M., Zhu, H., & Ekins, S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00546 · Cited by 152 · cited 2×
“However, there have also been arguments that ML models still can achieve better results compared with deep learning [42,169].”
BackgroundResultSelf-citationDesign of efficient computational workflows for in silico drug repurposing
Vanhaelen, Q., Mamoshina, P., Aliper, A. M., Artemov, A., Lezhnina, K., Ozerov, I., Labat, I., & Zhavoronkov, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.019 · Cited by 150 · cited 3×
“ML applications were also used in drug repurposing studies, as discussed in a previous review [95].”
BackgroundMethodInfluential
Cited by
Success stories of AI in drug discovery - where do things stand?
Mak, K.-K., Balijepalli, M. K., & Pichika, M. R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1985108 · Cited by 51
Machine learning in Alzheimer’s disease drug discovery and target identification
Geng, C., Wang, Z., & Tang, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102172 · Cited by 34
Metadata
- Authors
- Zhao, L., Ciallella, H. L., Aleksunes, L. M., & Zhu, H.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 25
- Issue
- 9
- Pages
- 1624-1638
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W3041306552
- Cited by
- 228
- References
- 47
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.